Fiche publication
Date publication
février 2015
Journal
Molecular pharmaceutics
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BENSOUSSAN Danièle
,
Pr GRANDEMANGE Stéphanie
,
Pr RIHN Bertrand
Tous les auteurs :
Safar R, Ronzani C, Diab R, Chevrier J, Bensoussan D, Grandemange S, Le Faou A, Rihn BH, Joubert O
Lien Pubmed
Résumé
S-Nitrosoglutathione (GSNO) is a good candidate for nitric oxide (NO(•)) delivery, and its nanoformulation improves NO(•) stability and bioavailability. We have compared the effect of empty Eudragit nanoparticles (eENP), GSNO-loaded ENP (gENP), and free GSNO on THP-1 human monocytic cell line. We investigated cellular viability and growth by WST-1 and trypan blue tests. ENP uptake was studied using transmission electron microscopy, confocal microscopy, and flow cytometry. Transcriptomic profiles were obtained using microarray. ENP entered cells by clathrin- and caveolae-mediated endocytosis. Exposure to either free GSNO or gENP induced an activation of genes from the same clusters, in favor of intracellular delivery of GSNO by ENP. GSNO nanoformulation might be a therapeutic option for NO(•) delivery.
Mots clés
Cell Line, Endocytosis, physiology, Humans, Microscopy, Electron, Transmission, Monocytes, metabolism, Nanoparticles, chemistry, Nitric Oxide, metabolism, S-Nitrosoglutathione, chemistry, Transcriptome, genetics
Référence
Mol. Pharm.. 2015 Feb;12(2):554-61
